Rheopheresis Mechanism in Hemodialysis Patients With PAD

Launched by UNIVERSITY HOSPITAL, GRENOBLE · May 10, 2022

Keywords

ClinConnect Summary

The main objective of our study is to evaluate the impact of rheopheresis on blood (main objective) and plasma viscosity, skin microcirculation and blood coagulation (Fibrinography, Thrombin Generation).

No study has evaluated the direct effect of rheopheresis on these different parameters.

However, a better understanding of these mechanisms would make it possible both to optimize the effectiveness of the technique, to limit its potential side effects and the cost of treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years or more and included in the RHEOPAD protocol (2019-A01513-54)
• • ESRD treated by hemodialysis or hemodiafiltration
• • PAD-LTI with tissue loss and/or wounds (ulcers or gangrene) with at least one of the following criterion, subject to the feasibility of the measures: arterial pressure assessment at the ankle \<70 mmHg, or toe pressure 30 mm Hg, or transcutaneous oximetry measurements \< 40 mm Hg
• • Interventional or surgical revascularization either not technically possible or no necessary
• • Medical insurance
• • Signed informed consent
• Exclusion Criteria:
• • - Uncontrolled infection despite well-conducted antibiotic therapy
• • Life expectancy \< 1 year
• • Severe cognitive or psychiatric disorders
• • Pregnant woman, parturient, nursing mother
• • Patients unable to give an informed consent or unwilling to participate in the study